Simon U Jaeger1, Thomas Klag2, Katharina Hoeger3, Siegfried Klumpp4, Markus Escher5, Nisar Malek2, Eduard Stange2, Jan Wehkamp2. 1. Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. 2. Department of Internal Medicine I, University Hospital, University of Tübingen, Tübingen, Germany. 3. Department of Gastroenterology and Hepatology, Robert Bosch Krankenhaus, Stuttgart, Germany. 4. Pharmacy, Robert Bosch Krankenhaus, Stuttgart, Germany. 5. Gastroenterologie Leonberg, Leonberg, Germany.
Abstract
BACKGROUND: Ulcerative proctitis may often be managed with topical salicylates or steroids alone, but in some patients, symptoms are persistent and severe. We analyzed the efficacy of tacrolimus suppositories in patients who had proven refractory to combined topical and systemic treatment. METHODS: In this retrospective analysis, ulcerative colitis activity index (CAI), side effects, co-medication and drug levels were assessed in 43 patients with distal ulcerative colitis who received suppositories containing 2 mg of tacrolimus b.i.d. as add-on medication. RESULTS: A total of 23 patients with ulcerative proctitis presented to follow-up within ≤50 days (mean 27.0 days) after suppositories were started. A decrease in CAI (from 8.0 to 5.5 points) was observed and 52.3% reached clinical remission (CAI ≤4). In total, 43 patients were available for analysis, of whom 9 had inflammation of the sigmoid colon as well. For the entire cohort, the median treatment duration was 76 days; 60% were in remission on the last documented visit. Serum measurements revealed a substantial tacrolimus level with a mean of 5.5 ng/mL. We observed one case of mild reversible acute kidney injury. CONCLUSIONS: In ulcerative proctitis, adding tacrolimus suppositories can be an effective and safe option when topical mesalazine, corticoid formulations and concomitant oral or parenteral medications have failed.
BACKGROUND: Ulcerative proctitis may often be managed with topical salicylates or steroids alone, but in some patients, symptoms are persistent and severe. We analyzed the efficacy of tacrolimus suppositories in patients who had proven refractory to combined topical and systemic treatment. METHODS: In this retrospective analysis, ulcerative colitis activity index (CAI), side effects, co-medication and drug levels were assessed in 43 patients with distal ulcerative colitis who received suppositories containing 2 mg of tacrolimus b.i.d. as add-on medication. RESULTS: A total of 23 patients with ulcerative proctitis presented to follow-up within ≤50 days (mean 27.0 days) after suppositories were started. A decrease in CAI (from 8.0 to 5.5 points) was observed and 52.3% reached clinical remission (CAI ≤4). In total, 43 patients were available for analysis, of whom 9 had inflammation of the sigmoid colon as well. For the entire cohort, the median treatment duration was 76 days; 60% were in remission on the last documented visit. Serum measurements revealed a substantial tacrolimus level with a mean of 5.5 ng/mL. We observed one case of mild reversible acute kidney injury. CONCLUSIONS: In ulcerative proctitis, adding tacrolimus suppositories can be an effective and safe option when topical mesalazine, corticoid formulations and concomitant oral or parenteral medications have failed.
Authors: A Dignass; J C Preiss; D E Aust; F Autschbach; A Ballauff; G Barretton; B Bokemeyer; S Fichtner-Feigl; S Hagel; K R Herrlinger; G Jantschek; A Kroesen; W Kruis; T Kucharzik; J Langhorst; M Reinshagen; G Rogler; D Schleiermacher; C Schmidt; S Schreiber; H Schulze; E Stange; M Zeitz; J C Hoffmann; A Stallmach Journal: Z Gastroenterol Date: 2011-08-24 Impact factor: 2.000
Authors: Jolanda M van Dieren; Ad A van Bodegraven; Ernst J Kuipers; Eke N Bakker; Alexander C Poen; Herman van Dekken; Edward E S Nieuwenhuis; C Janneke van der Woude Journal: Inflamm Bowel Dis Date: 2009-02 Impact factor: 5.325
Authors: K J Schmidt; K R Herrlinger; J Emmrich; D Barthel; H Koc; H Lehnert; E F Stange; K Fellermann; J Büning Journal: Aliment Pharmacol Ther Date: 2012-11-05 Impact factor: 8.171
Authors: Jolanda M van Dieren; Margaretha E H Lambers; Ernst J Kuipers; Janneke N Samsom; C Janneke van der Woude; Edward E S Nieuwenhuis Journal: Dig Dis Sci Date: 2009-12-01 Impact factor: 3.199
Authors: Evelyne Dubois; Annick Moens; Rob Geelen; João Sabino; Marc Ferrante; Séverine Vermeire Journal: United European Gastroenterol J Date: 2020-07-06 Impact factor: 4.623
Authors: Florian Uellendahl-Werth; Carlo Maj; Oleg Borisov; Simonas Juzenas; Eike Matthias Wacker; Isabella Friis Jørgensen; Tim Alexander Steiert; Saptarshi Bej; Peter Krawitz; Per Hoffmann; Christoph Schramm; Olaf Wolkenhauer; Karina Banasik; Søren Brunak; Stefan Schreiber; Tom Hemming Karlsen; Franziska Degenhardt; Markus Nöthen; Andre Franke; Trine Folseraas; David Ellinghaus Journal: Commun Biol Date: 2022-01-20